EICHOR
● Recruiting
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Condition: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · Sponsor: Dizal Pharmaceuticals
About this study
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD8586 versus investigator's choice in participants with chronic lymphocytic leukemia/small lymphocytic lymphoma who have progressed following prior therapy. Primary objective of this study is to assess the efficacy using progression free survival assessed by independent review committee as primary endpoint. Approximately 250 participants are estimated to be randomized into the study.
This description comes directly from the study's public registry record.
Talk to the study team
Cong Wei · 0086-21-61097873 · Cong.Wei@dizalpharma.com
Always discuss trial participation with your own doctor first.
Locations (2)
| First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital | Nanjing, Jiangsu, China | Recruiting |
| National Clinical Research Center for Blood Diseases, Blood Disease Hospital & Institute of Hematology, Chinese Academy of Medical Sciences & Peking Union Medical College | Tianjin, Tianjin Municipality, China | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07139873